Zacks: Analysts Anticipate ESSA Pharma Inc. (EPIX) to Announce -$0.18 EPS
Wall Street brokerages expect ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) to post earnings of ($0.18) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for ESSA Pharma’s earnings. ESSA Pharma reported earnings per share of ($0.19) in the same quarter last year, which indicates a positive year over year growth rate of 5.3%. The business is scheduled to announce its next earnings results on Wednesday, December 13th.
On average, analysts expect that ESSA Pharma will report full-year earnings of ($0.55) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.49). For the next financial year, analysts forecast that the company will post earnings of ($0.63) per share, with EPS estimates ranging from ($0.68) to ($0.57). Zacks’ EPS averages are a mean average based on a survey of sell-side research analysts that that provide coverage for ESSA Pharma.
EPIX has been the topic of several research analyst reports. Zacks Investment Research raised shares of ESSA Pharma from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 18th. Dawson James reissued a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Finally, Bloom Burton downgraded shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, September 12th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $4.75.
About ESSA Pharma
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.